Scioto Biosciences Inc.
Scioto Biosciences leverages discovery to improve lives by understanding and enhancing the healthy functions of good bacteria to prevent and treat many diseases. The company is focused on revolutionizing therapeutic interventions through its Activated Bacterial Therapeutic (ABT) platform, which enables beneficial bacteria colonization in the gut to address unmet medical needs related to the GI tract and the gut-brain axis. Scioto is developing SB-121 for the treatment of autism and other GI disorders, aiming to provide safe and efficacious options for patients. The company collaborates with leading research institutes and partners to advance microbiome therapeutics.
Industries
Nr. of Employees
small (1-50)
Scioto Biosciences Inc.
Products
Investigational biofilm-formulated probiotic for autism (early-phase clinical study)
An investigational orally administered probiotic formulation delivered in a biofilm state and evaluated in a Phase Ib randomized controlled trial in participants with autism spectrum disorder.
Biofilm-on-microsphere probiotic formulation for NEC prevention (preclinical)
Preclinical probiotic formulation where bacteria are adhered as a biofilm to semi-permeable microspheres containing beneficial cargo; demonstrated reduction in necrotizing enterocolitis incidence in an animal model after a single dose.
Investigational biofilm-formulated probiotic for autism (early-phase clinical study)
An investigational orally administered probiotic formulation delivered in a biofilm state and evaluated in a Phase Ib randomized controlled trial in participants with autism spectrum disorder.
Biofilm-on-microsphere probiotic formulation for NEC prevention (preclinical)
Preclinical probiotic formulation where bacteria are adhered as a biofilm to semi-permeable microspheres containing beneficial cargo; demonstrated reduction in necrotizing enterocolitis incidence in an animal model after a single dose.
Services
Platform development and licensing for live bacterial therapeutics
Development of a biofilm-based formulation platform for converting commensal bacteria into therapeutics and partnering/licensing with research organizations to advance programs.
Preclinical formulation and efficacy studies
Formulation of biofilm-on-microsphere probiotics and execution of animal efficacy studies to evaluate single-dose prophylactic or therapeutic effects in GI disease models.
Clinical operations and quality management for early-stage trials
Operational leadership and quality systems to support execution of Phase I clinical programs in indications such as autism spectrum disorder and necrotizing enterocolitis.
Platform development and licensing for live bacterial therapeutics
Development of a biofilm-based formulation platform for converting commensal bacteria into therapeutics and partnering/licensing with research organizations to advance programs.
Preclinical formulation and efficacy studies
Formulation of biofilm-on-microsphere probiotics and execution of animal efficacy studies to evaluate single-dose prophylactic or therapeutic effects in GI disease models.
Clinical operations and quality management for early-stage trials
Operational leadership and quality systems to support execution of Phase I clinical programs in indications such as autism spectrum disorder and necrotizing enterocolitis.
Expertise Areas
- Live bacterial therapeutics
- Biofilm-based formulation and encapsulation
- Oral microbiome delivery systems
- Preclinical models for gastrointestinal disease (NEC, C. difficile)
Key Technologies
- Biofilm-based bacterial formulation
- Semipermeable biocompatible microsphere encapsulation
- Prebiotic cargo loading into microparticles
- In vitro epithelial adherence assays